Skip to main content

A model approach to estimate Staphylococcus aureus intramammary infection dynamics for different scenarios when vaccinating for mastitis


Petzer, I. M.; Karzis, J.; Eric Etter, E.

The model revealed that the use of this mastitis vaccine provided additional benefits to combat S. aureus IMI in both high and low transmission risk scenarios. Less clinical cases occurred from the first time cycles but the advantages intensified with duration of use.

When new remedies or treatments are considered for used in a farming enterprise the main concern is whether the benefit will outweigh the cost and predicted losses. Benefits however should not only be measured in economic terms. In addition to stochastic partial budget models that estimate cost and benefits when using STARTVAC® (HIPRA) mastitis vaccine, a model was developed to calculate the intramammary infection (IMI) dynamics of Staphylococcus aureus (S. aureus).

Download this article